

—Inflation Reduction Act Research Series— Xarelto: Medicare Enrollee Use and Spending

This Fact Sheet provides information on **Xarelto**, one of the 10 drugs selected for the first cycle of Medicare drug price negotiations. Xarelto (active ingredient rivaroxaban) is a small molecule drug used to prevent and treat blood clots and reduce risk for patients with coronary or peripheral artery disease. Medicare enrollees may have a high risk of blood clots due to age and other comorbidities present among this population.

- Between 2018 and 2022, average annual total Part D spending per enrollee taking Xarelto (i.e., the total amount, including Medicare, plan, and enrollee payments, spent on Xarelto per person) increased by 38 percent (from \$3,197 to \$4,402).
- From 2018 through 2022, the average annual out-of-pocket spending per enrollee increased by 26 percent (from \$357 to \$451).

Table 1 presents data on utilization and spending for Xarelto among Part D enrollees. About 1.3 million Part D enrollees filled prescriptions for Xarelto in 2022. Relative to the total Part D population, a greater share of Xarelto users were men (51 percent vs. 44 percent), ages 75 or older (49 percent vs. 37 percent), and White non-Latinos (79 percent vs. 72 percent).

Table 1. Medicare Part D Use and Spending on Xarelto, Calendar Year (CY) 2022

	Total Enrollees	LIS Enrollees ^a	Non-LIS Enrollees
Number of Part D Enrollees	53,063,000	14,957,000	38,106,000
Number of Enrollees Taking Xarelto	1,311,000	370,000	941,000
Share of Part D Enrollees Taking Xarelto	3%	3%	3%
Total Spending on Xarelto			
Total Spending	\$5,773,111,000	\$1,664,938,000	\$4,108,174,000
Average per Enrollee taking Xarelto	\$4,402	\$4,496	\$4,365
Enrollee Out-of-Pocket Spending on Xarelto			
Total OOP Spending	\$591,609,000	\$11,011,000	\$580,598,000
Average OOP per Enrollee taking Xarelto	\$451	\$30	\$617

Notes: ^aFor eligible Part D enrollees who meet income and asset requirements, the Low-Income Subsidy (LIS), also known as Extra Help, provides assistance with premiums, deductibles, and co-payments for covered Part D drugs.

The Inflation Reduction Act was signed into law by President Biden in August 2022. Please see [here](#) for more information on how the law is reducing drug costs for Medicare beneficiaries.

Please see [here](#) for more information on Xarelto and the other drugs selected for the first cycle of Medicare drug price negotiation, cautions and limitations in interpretation and use of these estimates, and relevant citations.